GSK-269984A is a Prostaglandin E2 Receptor 1 (EP1) antagonist with a pIC 50 of 7.9.
In Vitro
Results from [ 3 H]-PGE 2 binding assay in CHO cells overexpressing the human EP 1 receptor demonstrate that GSK-269984A is an antagonist of EP 1 receptor with a pIC 50 of 7.9. GSK-269984A is found to cause a concentration-dependent rightward shift of the PGE 2 dose-response curve and Schild analysis shows that GSK-269984A is a competitive antagonist with pA 2 8.1±0.3 and slope 1.0. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
GSK-269984A demonstrates an ED 50 of 2.6 mg/kg (po), with the 10 mg/kg dose showing equivalent reversal of hypersensitivity to the standard. GSK-269984A displays moderate blood clearance in the rat\nand dog and high clearance in the monkey which is reflected in the half-life for each species . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:EP1 7.9 (pIC 50 )
规格
英文别名
Q27280309 | GSK269984A | GSK-269984A | 2-Pyridinecarboxylic acid, 6-((5-chloro-2-((4-chloro-2-fluorophenyl)methoxy)phenyl)methyl)-, sodium salt (1:1) | Sodium 6-((5-chloro-2-(((4-chloro-2-fluorophenyl)methyl)oxy)phenyl)methyl)-2-pyridinecarboxylate | UNII